yellow
fever
vaccineassoci
viscerotrop
diseas
yelavd
rare
complic
yellow
fever
yf
vaccin
previous
healthi
femal
die
follow
yf
vaccin
despit
aggress
measur
serial
viral
load
titer
cytokin
level
host
genet
factor
evalu
attempt
understand
unusu
lethal
outcom
patient
hightit
vaccin
viremia
possibl
relat
minor
genet
anomali
provid
clue
explor
etiolog
yelavd
sinc
live
attenu
yf
viru
vaccin
protect
million
human
yf
mosquitotransmit
diseas
case
fatal
rate
sinc
late
case
yelavd
character
multiorgan
failur
record
worldwid
follow
administr
vaccin
manufactur
unit
state
franc
brazil
china
center
diseas
control
prevent
cdc
unpublish
data
risk
yelavd
three
per
million
dose
administ
highest
among
peopl
year
age
histori
thymic
diseas
incid
yelavd
per
dose
peopl
age
year
per
dose
peopl
year
older
howev
nine
record
case
less
year
age
none
thymic
diseas
cdc
unpublish
data
recognit
yelavd
coincid
decreas
use
pretravel
immunoglobulin
prevent
hepat
lead
conjectur
may
prevent
past
fortuit
coadministr
antibodi
yf
viru
yfv
hypothes
explain
yelavd
includ
genet
host
suscept
gener
rare
mutat
replic
host
increas
virul
healthi
student
receiv
tetanusdiphtheria
hepat
typhoid
vaccin
prior
trip
bolivia
eight
day
later
receiv
yf
vaccin
two
day
vaccin
note
red
swell
pain
inocul
site
three
day
later
present
emerg
depart
ipsilater
axillari
adenopathi
myalgia
fever
vomit
temperatur
f
puls
respir
blood
pressur
physic
examin
unremark
except
enlarg
tender
axillari
lymph
node
white
blood
cell
count
wbc
cellsmm
neutrophil
hemoglobin
platelet
count
normal
aspart
aminotransferas
ast
ul
intern
normal
ratio
inr
proteinuria
tabl
chest
radiograph
electrocardiogram
normal
blood
cultur
neg
admit
given
intraven
fluid
analges
antiemet
improv
initi
h
later
develop
abdomin
pain
loos
stool
recurr
fever
wbc
drop
cellsmm
hemoglobin
gdl
platelet
per
mm
ast
increas
ul
total
bilirubin
mgdl
inr
renal
function
initi
preserv
transfer
intens
care
unit
icu
quaternari
care
hospit
day
yf
vaccin
complain
pleurit
chest
pain
dyspnea
worsen
abdomin
pain
chest
radiograph
show
pleural
effus
fig
transthorac
echocardiogram
reveal
tamponadelik
physiolog
secondari
surround
pleural
effus
pleural
fluid
cultur
hiv
serolog
neg
anur
renal
failur
ensu
requir
hemodialysi
labil
blood
pressur
preclud
fluid
remov
singl
g
dose
intraven
immunoglobulin
ivig
administ
hydrocortison
initi
mg
intraven
everi
h
laboratori
paramet
progress
worsen
tabl
nine
day
vaccin
develop
hypoxem
respiratori
failur
requir
mechan
ventil
repeat
chest
radiograph
show
dens
bilater
consolid
nitric
oxid
therapi
initi
follow
day
vasopressor
start
hypotens
unrespons
fluid
resuscit
high
frequenc
oscillatori
ventil
follow
extracorpor
membran
oxygen
initi
refractori
hypoxemia
repeat
transthorac
echocardiogram
reveal
markedli
depress
eject
fraction
broadspectrum
antibiot
start
consult
infecti
diseas
servic
convinc
evid
bacteri
infect
pleural
fluid
eleven
day
yf
vaccin
patient
die
blood
cultur
drawn
immedi
prior
death
grew
group
c
betahemolyt
streptococcu
pleural
fluid
sampl
grew
streptococcu
staphylococcu
aureu
postmortem
examin
reveal
multiorgan
failur
diffus
hemorrhag
consist
dissemin
intravascular
coagul
dic
fig
microscopi
lung
show
diffus
alveolar
damag
hemorrhag
acut
necrot
bronchopneumonia
postmortem
blood
cultur
grew
aureu
formalinfix
paraffinembed
tissu
sent
cdc
histopatholog
immunohistochem
ihc
evalu
serum
plasma
sampl
test
viremia
immunolog
respons
consensu
sequenc
viru
isol
obtain
blood
compar
lot
use
vaccin
three
refer
strain
isol
young
femal
die
spain
follow
vaccin
genbank
access
number
respect
cytokin
level
assess
beadlyt
human
multicytokin
detect
system
cat
respect
upstat
usa
inc
va
patient
level
compar
previous
store
serum
four
healthi
unvaccin
peopl
patient
dna
isol
whole
blood
use
analyz
sequenc
select
gene
might
influenc
vaccin
respons
yfv
antigen
detect
ihc
kidney
liver
spleen
heart
lung
histopatholog
find
liver
includ
microvesicular
steatosi
councilman
bodi
seen
wildtyp
yf
panacinar
necrosi
presum
secondari
dic
repeat
bout
hypotens
predomin
classic
find
midzon
necrosi
tissu
stain
reveal
abund
coloni
gramposit
gramvari
cocci
inflammatori
infiltr
lung
ihc
stain
identifi
coloni
aureu
vaccin
strain
rna
amplifi
plasma
serum
sampl
rtpcr
estim
viral
titer
plaqueform
unit
pfu
ml
postvaccin
day
rise
peak
pfuml
follow
day
tabl
healthi
vaccin
peopl
rare
greater
pfuml
viremia
drop
day
vaccin
develop
yf
virusspecif
neutral
igm
antibodi
viral
rna
thereaft
detect
low
level
day
death
elev
level
sever
proinflammatori
cytokin
chemokin
includ
tabl
serum
level
viremia
antibodi
select
cytokin
neut
ab
neutral
antibodi
igm
immunoglobulin
ifn
interferon
tnf
tumor
necrosi
factor
il
interleukin
rant
regul
activ
normal
cell
express
secret
gmcsf
granulocyt
macrophag
colonystimul
factor
mcp
monocyt
chemotact
protein
mip
macrophag
inflammatori
protein
ip
interferondeltainduc
protein
nd
determin
cytokin
level
express
high
low
baselin
compar
four
healthi
recipi
yellow
fever
vaccin
rant
gmcsf
clinic
cours
specif
cytokin
abnorm
would
explain
ill
consensu
sequenc
viral
rna
obtain
day
postvaccin
show
nucleotid
ident
util
vaccin
lot
sequenc
differ
refer
strain
asn
thr
silent
silent
silent
silent
noncod
ident
chang
posit
detect
viral
rna
recent
fatal
case
spain
spanish
isol
also
uniqu
silent
mutat
comparison
patient
gene
promot
exon
sequenc
genbank
human
genom
assembl
nt
nw
reveal
differ
howev
minor
allel
detect
three
previous
identifi
singl
nucleotid
polymorph
snp
gene
gghomozyg
snp
exon
gghomozyg
snp
intron
splice
acceptor
site
aahomozyg
snp
aindel
termin
exon
frequenc
snp
gghomozygot
vari
european
subsaharan
african
frequenc
snp
gghomozygot
snp
aahomozygot
variat
sequenc
regulatori
element
gene
promot
observ
singl
variat
within
exon
patient
aahomozyg
snp
caus
prematur
stopcodon
exon
frequenc
aahomozygot
vari
africanamerican
caucasian
patient
homozyg
minor
allel
one
four
snp
cc
frequenc
promot
region
one
five
snp
exon
ncr
tt
frequenc
heterozyg
snp
intron
intron
silent
exon
mutat
detect
either
promot
exon
tolllik
receptor
gene
homozyg
wildtyp
snp
analyz
gene
promot
rant
promot
dcsign
gene
dcsignr
gene
heterozyg
number
repeat
exon
develop
yelavd
could
due
either
viral
host
anomali
consensu
viral
rna
sequenc
obtain
patient
blood
ident
origin
vaccin
lot
indic
primari
strain
mutat
inocul
although
sequenc
differ
refer
vaccin
strain
also
detect
isol
similar
case
yelavd
spain
two
nucleotid
chang
silent
one
noncod
region
chang
seem
unlik
affect
virul
peopl
vaccin
lot
develop
yelavd
clonal
sequenc
viru
earlier
yelavd
case
reveal
mutat
vaccin
substrain
mutat
viru
also
isol
child
enceph
follow
yf
vaccin
sinc
clonal
sequenc
isol
patient
done
possibl
minor
mutant
substrain
alter
overal
virul
vaccin
without
alter
consensu
sequenc
howev
viral
sequenc
yelavd
case
suggest
loss
attenu
yelavd
occur
vaccin
variou
lot
strain
subtyp
manufactur
one
eight
gene
mice
associ
suscept
flavivirus
three
snp
minor
allel
homozyg
patient
gene
two
code
region
intron
splice
site
least
five
differ
isoform
gener
altern
splice
isoform
produc
genotyp
aallel
intron
snp
produc
gallel
produc
sinc
patient
gghomozyg
would
produc
comput
model
suggest
may
impair
enzymat
activ
patient
homozyg
gallel
snp
exon
caus
amino
acid
substitut
isoform
gallel
snp
previous
report
associ
sever
acut
respiratori
syndrom
vietnames
popul
homozygos
termin
exon
ainsert
produc
frame
shift
prematur
translat
termin
transcript
although
current
support
experiment
data
three
minor
allel
gene
aahomozygos
snp
lead
truncat
protein
could
advers
effect
possibl
oasmedi
antiflavivir
activ
contribut
abnorm
high
viru
level
unlik
mutat
pkr
affect
protein
function
mutat
candid
gene
evalu
might
also
influenc
respons
yf
vaccin
similar
host
factor
may
involv
atyp
sever
manifest
differ
flaviviru
infect
follow
vaccin
patient
develop
notabl
inflamm
vaccin
site
viru
thought
replic
dendrit
cell
local
inflamm
may
occur
vaccin
rare
sever
describ
prior
case
report
signific
sever
local
inflamm
uncertain
might
consist
increas
viral
replic
higher
intens
local
immun
respons
patient
viremia
peak
postvaccin
day
time
higher
expect
follow
brief
remiss
intensif
symptom
time
multiorgan
failur
develop
like
mediat
inflammatori
cytokin
clinic
pattern
similar
seen
wildtyp
yf
except
viru
usual
clear
wildtyp
infect
day
one
dose
ivig
given
postvaccin
day
without
obviou
clinic
benefit
dose
withheld
volum
overload
concern
gener
consensu
patient
develop
protect
antibodi
respons
ivig
propos
postexposur
prophylaxi
wildtyp
yf
proven
benefit
onset
ill
patient
clinic
cours
complic
bacteri
pneumonia
sepsi
secondari
bacteri
infect
also
occur
patient
natur
acquir
yf
use
prophylact
antibiot
may
consequ
warrant
person
yelavd
futur
yf
vaccin
effect
mean
prevent
wildtyp
diseas
howev
potenti
extrem
rare
sever
advers
event
vaccin
given
travel
whose
itinerari
requir
vaccin
etiolog
mechan
yelavd
remain
unclear
may
vari
across
case
genet
suscept
base
oa
gene
abnorm
might
play
role
case
suspect
case
yelavd
promptli
report
vaccin
advers
event
surveil
system
http
vaershhsgov
collect
whole
blood
serum
patient
suspect
yelavd
aid
futur
investig
puzzl
devast
condit
